<DOC>
	<DOCNO>NCT00009217</DOCNO>
	<brief_summary>The optimal strategy treatment behavioral complication patient probable Alzheimer 's disease ( AD ) remain unclear . The objective study evaluate risk relapse follow discontinuation haloperidol patient Alzheimer 's disease ( AD ) psychosis agitation respond . In Phase A study , AD outpatients behavioral complication receive 20 week open haloperidol treatment oral dose 1-5 mg daily , titrate individually achieve optimal trade-off efficacy side effect . Responders Phase A participate Phase B , 24-week continuation trial patient randomize continuation haloperidol placebo . The primary outcome time relapse psychosis behavioral disturbance .</brief_summary>
	<brief_title>Treatment Behavioral Symptoms Alzheimer 's Disease</brief_title>
	<detailed_description>The study involve two phase . Outpatients AD meet inclusion/ exclusion criterion enter Phase A , 20 week open acute treatment phase use flexible dose regimen haloperidol 1-5 mg daily . Haloperidol start oral dose 1 mg daily , subsequent dose titration 1 mg increment optimal dose reach , i.e. , optimal trade-off efficacy side effect . At end Phase A , patient meet criteria clinical response exit protocol treat openly alternative medication . Phase A responder enter Phase B , 24-week random assignment , placebo-controlled , continuation trial . Randomization stratify severity dementia presence psychosis . Half patient randomize haloperidol ( continue dose end Phase A ) , half randomize placebo . Patients relapse Phase B exit protocol receive open treatment . In Phase A , patient follow 0 , 2 , 4 week every 4 week thereafter 20 week . In discontinuation trial , Phase B , patient follow 0 , 1 , 2 , 4 , week time point every 4 week thereafter 24 week . If patient show sign relapse , patient bring frequent visit , regardless stage protocol .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Behavioral Symptoms</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<criteria>Meets DSMIV criterion dementia either sex , age 5095 year Meets NINCDSADRDA criterion probable Alzheimer 's disease Meets Folstein MiniMental State Exam score 526 , inclusive Intellectual impairment report least six month Availability family member direct contact patient average least every week three month prior study entry Has current symptom psychosis agitation . Criteria `` psychosis '' require presence delusion and/or hallucination identify Columbia University Scale Psychopathology Alzheimer 's Disease ( CUSPAD ) minimum Brief Psychiatric Rating Scale ( BPRS ) psychosis factor score least 4 ( moderate severity ) one follow two item : These two item comprise psychosis factor , exclude item conceptual disorganization . Agitation define score great 3 ( present least 10 day per month ) one CERAD Behavioral Rating Scale Dementia item agitation , purposeless wandering , verbal aggression physical aggression . Free psychotropic medication least two week prior study entry , able tolerate medication washout period . Informed consent patient family member , per IRB procedures New York State Psychiatric Institute . Acute unstable medical condition , delirium , alcohol substance abuse dependence within past 1 year Clinical evidence stroke , dementias include vascular Lewy body frontotemporal dementia , multiple sclerosis , Parkinson 's disease , Huntington 's disease , tardive dyskinesia Diagnosis psychotic disorder antedate onset dementia Antipsychotic medication usage 4 week prior study entry Contraindication use haloperidol</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>psychosis</keyword>
	<keyword>agitation</keyword>
	<keyword>haloperidol</keyword>
</DOC>